- $2.18m
- $15.60m
- $7.68m
Respiratory drugmaker Beyond Air Q2 net loss misses estimates
Brief: Beyond Air Secures Up To $32 Million Financing
Brief: NeuroNOS Wins FDA Orphan Drug Status for Glioblastoma Therapy
Beyond Air Inc reports results for the quarter ended June 30 - Earnings Summary
Beyond Air Inc expected to post a loss of $1.40 a share - Earnings Preview
Brief: Beyond Air FY Net Income USD -48.479 Million
Beyond Air Inc reports results for the quarter ended March 31 - Earnings Summary
Beyond Air Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Neuronos gets $2 mln funding for development of autism therapy
Brief: Beyond Air signs agreements expanding global distribution of LungFit PH
Beyond Air Inc reports results for the quarter ended December 31 - Earnings Summary
Beyond Air Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Beyond Air Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing
Advisory: Ignore incorrect advisory alert on Beyond Cancer coding error
Brief: Beyond Air Receives CE Mark in Europe for the LungFit® PH System
Brief: Neuronos Appoints Nobel Laureate, Roger D. Kornberg, To Scientific Advisory Board
Beyond Air Inc reports results for the quarter - Earnings Summary
Beyond Air Inc expected to post a loss of 28 cents a share - Earnings Preview
Brief: Avenue Capital Management II Reports 14.7% Passive Stake In Beyond Air Inc As Of September 26 - SEC Filing